UNSPSC 51312610: Antazoline sulfate

This classification denotes a histamine-1 receptor antagonist with the molecular formula 2C17H19N3.2H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6T74I07212. European Medicines Agency schedules antazoline sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00542MIG. The term antazoline sulfate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule antazoline sulfate under HS 29332990 and SITC 51573.

As of Q4 2014, ANTAZOLINE SULFATE remains US FDA's Preferred Term for this commodity. Antazoline sulfate bears US NLM identifiers UMLS ID C0770941 and NCI Concept Code C95310. SMILES: C1CCC(CC1)CN(CC2=NCCN2)C3CCCCC3.OS(=O)(=O)O.

UNSPSC 51312610 Antazoline sulfate is a Commodity code that in recent state and local activity encompasses pharmaceutical products and related procurement services, though the available opportunities do not directly reference antazoline sulfate itself. State and local governments buying under this code or related pharmaceutical UNSPSC categories are procuring naloxone, generic multi-source pharmaceuticals, over-the-counter (OTC) products, and drug deactivation systems through a mix of county health departments, state health and human services agencies, and cooperative purchasing alliances. These procurements typically require vendors to supply products through authorized wholesaler networks, comply with FDA manufacturing standards and Drug Supply Chain Security Act (DSCSA) requirements, maintain specified insurance coverage including commercial general liability, and meet E-Verify and drug-free workplace certification. Issuing bodies include county governments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: the due date appears inconsistent with the posting date in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program targeting direct contracting between state pharmacy benefit programs and manufacturers. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026, and awarded contracts effective July 1, 2026. The MMCAP procurement weights price competitiveness at 75 percent, requires vendors to maintain relationships with at least two of the three authorized wholesalers, and imposes a 3 percent administrative fee on all purchases.